|
1
|
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.
|
J Clin Oncol
|
2009
|
2.63
|
|
2
|
A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.
|
Clin Cancer Res
|
2014
|
1.35
|
|
3
|
Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors.
|
Clin Cancer Res
|
2010
|
1.30
|
|
4
|
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.
|
Clin Cancer Res
|
2012
|
1.27
|
|
5
|
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
|
J Clin Oncol
|
2010
|
1.15
|
|
6
|
The Pim kinases: new targets for drug development.
|
Curr Drug Targets
|
2011
|
1.06
|
|
7
|
Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors.
|
Mol Cancer Ther
|
2011
|
0.98
|
|
8
|
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
|
Cancer Chemother Pharmacol
|
2011
|
0.96
|
|
9
|
A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.
|
Clin Cancer Res
|
2008
|
0.89
|
|
10
|
Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
|
Clin Cancer Res
|
2013
|
0.87
|
|
11
|
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
|
Clin Cancer Res
|
2012
|
0.87
|
|
12
|
Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors.
|
Cancer Chemother Pharmacol
|
2012
|
0.86
|
|
13
|
Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
|
Invest New Drugs
|
2012
|
0.84
|
|
14
|
Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
|
Expert Opin Drug Metab Toxicol
|
2009
|
0.83
|
|
15
|
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2008
|
0.83
|
|
16
|
Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
|
Cancer Chemother Pharmacol
|
2008
|
0.81
|
|
17
|
Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2011
|
0.81
|
|
18
|
Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
|
Clin Cancer Res
|
2009
|
0.81
|
|
19
|
Phase I study of GRN1005 in recurrent malignant glioma.
|
Clin Cancer Res
|
2013
|
0.81
|
|
20
|
Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors.
|
Clin Cancer Res
|
2013
|
0.80
|
|
21
|
RANK ligand: effects of inhibition.
|
Curr Oncol Rep
|
2010
|
0.80
|
|
22
|
Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.
|
Cancer Chemother Pharmacol
|
2014
|
0.80
|
|
23
|
A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2011
|
0.79
|
|
24
|
Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors.
|
Invest New Drugs
|
2014
|
0.78
|
|
25
|
Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2014
|
0.76
|
|
26
|
Predicting success in regulatory approval from Phase I results.
|
Cancer Chemother Pharmacol
|
2014
|
0.75
|
|
27
|
Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors.
|
Cancer Chemother Pharmacol
|
2014
|
0.75
|
|
28
|
Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
|
Int J Clin Pharmacol Ther
|
2015
|
0.75
|